-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Inside BIO Industry Analysis
Only 12% of Public Biotechs are Profitable
Of the 286 biotech companies trading on public exchanges today, 241 focus on drug development, a slight drop in numbers from last year.* Of these 241 in the biopharmaceutical space, only 28 (12%) had both a product on the market and positive net income for FY 2012. This is about the same as the 13% reported last year, but different companies populate the list. Unlike our last report (May 2012), when acquisitions of profitable companies Read More >
Breakthrough Designations Reach 13
One of the outcomes of the 2012 Food and Drug Administration Safety and Innovation Act (FDASIA) was the creation of the “Breakthrough Therapy” designation. The new law allows FDA to grant a Breakthrough Therapy designation to drugs showing early clinical promise for serious or life-threatening conditions, thereby expediting both the development and the review of these drugs. As of today, 13 designations have been granted according to a search of the BioMedTracker database (see table Read More >
Results from the BIO Convention 2013 Meeting Analysis of Therapeutic In/Out Licensors
BIO’s results from the BIO 2013 Convention 1×1 meeting analysis conducted to identify trends and intentions of therapeutic in-licensors and out-licensors were released today. The analysis looked at the meeting activity of 180 in-licensors attending the Chicago conference in terms of what therapeutic areas and stages of development were in highest demand. Of the 804 drug R&D companies, companies in Phase I/Rare Disease came out ahead as a group, with an average of >17 meetings/company. This was followed by Phase Read More >
Evidence, Coverage, & Incentives: A PMC/BIO Solutions Summit Conference
Personalized medicine is changing the way medicine is practiced, and how drugs and biologics are developed. Systemic changes are needed to reflect this and support product development, but current economic, regulatory, and practice disincentives are impacting and slowing development. For example, medical advances often take years to be recognized in clinical care guidelines and cost containment policies often prevent new diagnostics from being priced at a level that supports innovation. The Personalized Medicine Coalition (PMC) and Read More >
BIO-Europe Spring Opening Remarks
BIO’s own David Thomas, Director of Industry Research, delivered opening remarks at the BIO-Europe Spring conference in Barcelona yesterday. His slides provide a snapshot of the biotech industry’s performance and highlight emerging trends in venture exits: IPOs and M&A. Takeaways from his talk include breakouts on multiple fronts for the industry: FDA approvals at highs not seen since the 1990s Orphan designation approvals at all-time highs IPOs starting to show signs of life in 2012 Read More >
